Switch to:
More From Other Websites
Merck CEO Ken Frazier Is A Quote Machine Dec 04 2016
Tech Data’s board gets more diverse with addition of former Merck executive Dec 02 2016
Merck & Co., Inc. (MRK) Gets Coveted Approval For Keytruda Dec 02 2016
AbbVie’s Venclexta May Become Promising Multiple Myeloma Therapy Dec 02 2016
Acute Myeloid Leukemia: Growth Opportuny for AbbVie’s Venclexta? Dec 02 2016
Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma Dec 02 2016
Merck KGaA (MKGAF) Expands Distribution Deal with Roche Dec 02 2016
Keytruda Is Merck’s Immuno-Oncology Business Dec 02 2016
Label Expansion May Boost Venclexta’s Growth Prospects Dec 02 2016
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda Dec 02 2016
Merck wins UK okay for Keytruda in lung cancer after price cut Dec 01 2016
Pharma execs weigh in on possible changes under Trump Dec 01 2016
Recent R&D Developments from Merck You Won’t Want to Miss Dec 01 2016
What’s Forcing Valeant to Sell Its Core Assets? Dec 01 2016
Bringing foreign drugs into the US market is a dangerous ... Dec 01 2016
Alexandria Real Estate, Merck Ink Long-Term Pharma Lease Dec 01 2016
FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Merck’s... Dec 01 2016
AbbVie’s Plans for ABT-555, a Novel Multiple Sclerosis Therapy Dec 01 2016
Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study Dec 01 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK